TL;DR
This study combines genome-wide and transcriptome-wide association studies to identify genetic risk factors for Amyotrophic Lateral Sclerosis (ALS) in Northern New England and Ohio. It highlights a known ALS risk variant in the TARDBP gene and suggests ZNF235 as a potential novel risk gene, while also exploring gene-smoking interactions.
What Problem Does This Paper Address?
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease with a largely unknown genetic basis. While some genetic risk factors have been identified, they only explain a small portion of the disease's heritability. Furthermore, environmental factors like smoking are known to increase ALS risk, suggesting a complex interplay between genes and environment that needs further investigation. This study aims to shed light on these genetic underpinnings, particularly in the Northern New England region, which has shown an elevated prevalence of ALS.
Methods
The researchers employed two primary approaches:
- Genome-Wide Association Study (GWAS): This standard technique scans the entire genome for single nucleotide polymorphisms (SNPs) associated with ALS. They used the Illumina NeuroChip array for genotyping and performed covariate-adjusted logistic regression to estimate odds ratios.
- Transcriptome-Wide Association Study (TWAS): This method uses predicted gene expression levels to identify associations with disease risk. They utilized PrediXcan, which leverages existing genotype and gene expression data to predict expression levels across various tissues (13 brain tissues, skeletal muscle, and whole blood) and then tested these predictions against ALS risk.
They also conducted a SNP-smoking interaction screening to explore how smoking might modify the effect of genetic variants on ALS risk.
Datasets
- Primary Cohort: 435 ALS cases and 279 controls from Northern New England and Ohio.
- Validation Cohort: Data from dbGaP, including 10,067 ALS cases and 2,251 controls, with an additional 11,887 controls from two other dbGaP datasets.
- Reference Data for TWAS: PredictDB, which uses the Genotype-Tissue Expression (GTEx) version 7 reference panel.
- Imputation Reference: European population data from the 1000 Genomes Project (phase 3, version 5).
Key Insights and Ideas
- TARDBP Variant Confirmation: The study confirmed a previously identified missense variant (p.A382T) in the TARDBP gene as a significant risk factor for ALS. This variant is particularly prevalent in the Sardinian population, suggesting potential founder effects or shared ancestry.
- ZNF235 as a Novel Candidate: Both GWAS and TWAS pointed towards ZNF235 as a gene associated with ALS risk. The TWAS results showed that lower predicted expression of ZNF235 in brain and skeletal muscle tissues was linked to a higher risk of ALS, suggesting a potential protective role for this gene.
- Gene-Environment Interaction Potential: The exploration of SNP-smoking interactions identified suggestive associations with variants in GDF3 and MYOSB. This reinforces the idea that environmental factors like smoking can interact with genetic predispositions to influence ALS development.
- TWAS for Tissue-Specific Insights: The TWAS approach allowed the researchers to investigate gene expression in a variety of tissues, providing a more nuanced understanding of how genetic variations might impact different biological systems relevant to ALS.
Key Results
- GWAS: Identified 15 genes with suggestive statistical significance (p < 1E-5). The most significant finding was the TARDBP variant rs367543041 (p = 3.95E-6).
- SNP-Smoking Interactions: Identified 19 SNPs from 7 cytogenetic locations showing evidence of interaction with smoking (p < 1E-5). Two genes, GDF3 and MYOSB, were highlighted for their suggestive interactions.
- TWAS: Identified 8 genes with suggestive associations with ALS risk (FDR < 0.30) across 5 tissues. Notably, ZNF235 showed suggestive associations in brain caudate and skeletal muscle tissues.
Limitations and Future Work
- Modest Sample Size: The primary cohort's relatively small size limited the power to detect genome-wide significant associations and may have contributed to the failure to identify associations with some known ALS genes.
- Validation Challenges: The TARDBP variant could not be directly validated in the larger dbGaP dataset due to differences in genotyping platforms. Proxy SNPs were used, providing tentative support. Smoking data was also unavailable for the validation cohort, preventing replication of interaction findings.
- European Ancestry Focus: The study was restricted to individuals of European ancestry, limiting the generalizability of findings to other populations.
- Future Directions: The authors emphasize the need for larger sample sizes, harmonized genotyping arrays, and studies across diverse ancestral and geographical groups. They also plan to integrate geographic information system technology and pollution databases to explore gene-environment interactions further. Follow-up genetic research is crucial to elucidate the role of identified variants and genes in motor neuron degeneration.
Summary updated